HER2 status of gastric carcinoma and corresponding lymph node metastasis

Pathology and Oncology Research

Volumn 19, Issue 1, 2013, Pages 103-109

  Pagni, Fabio ^a,b   Zannella, Stefano ^a,b   Ronchi, Susanna ^a,b   Garanzini, Cristina ^a,b   Leone, Biagio Eugenio ^a,b  

^a DESIO HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Gastric cancer; HER2; HER2 status scoring system; IHC; Metastasis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; FEMALE; GASTRECTOMY; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MOLECULAR PATHOLOGY; OBSERVER VARIATION; ONCOLOGICAL PARAMETERS; PRACTICE GUIDELINE; PRIMARY TUMOR; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; SCORING SYSTEM; STOMACH CARCINOMA; TUMOR LOCALIZATION;

AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84873091365     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-012-9564-2     Document Type: Article

References (8)

1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase III, open-label, randomised controlled trial. Lancet 376:687-97
2. Hoffmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:797-805
3. Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Höfler H, Kreipe HH (2010) HER2 diagnostics in gastric cancer: guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457:299-307
4. Wolff AC, Hammond EH M, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for Human Epidermal Growth Factor Receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18-43
5. Albarello L, Pecciarini L, Doglioni C (2011) HER2 Testing in gastric cancer. Adv Anat Pathol 18:53-59
6. Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, Gardini G, Nizzoli R, Leonardi F, Gasparro D, Camisa R, Cavalli S, Silini EM, Ardizzoni A (2011) Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 104:1372-1376
7. Nassar A, Cohen C, Agersborg SS, Zhou W, Lynch KA, Albitar M, Barker EA, Vanderbilt BL, Thompson J, Heyman ER, Lange H, Olson A, Siddiqui MT (2001) Trainable Immunohistochemical HER/neu Image Analysis. A multisite performance study using 260 breast tissue specimen. Arch Pathol Lab Med 135:896-902
8. Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH, Bokemeyer C, Izbicki JR, Sauter G (2009) HER-2 amplification is highly homogeneous in gastric cancer. Hum Pathol 40:769-777